Antagonic Effect of Soursop Leaf Aqueous Extract and Doxorubicin Combination in MCF7 and T47D Breast Cancer Cell

Miranti Kania Dewi,1 Siti Annisa Devi Trusda,2 Lelly Yuniarti3
1Department of Pharmacology, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia,
2Department of Histology, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia,
3Department of Biochemistry, Nutrition, and Biomolecular, Faculty of Medicine, Universitas Islam Bandung, Bandung, Indonesia

Abstract
The success of breast cancer therapy is still not optimal and the side effects caused by breast cancer therapy. The use of standard drug combinations with herbs is often used as co-chemotherapy and is believed to increase the drug’s effectiveness. However, research on the antagonistic effect of the drug combination is still minimal. This study examines the anticancer effect of soursop leaf aqueoxes extract and the combined impact of doxorubicin on MCF7 and T47D breast cancer cells. This research is pure in vitro experimental study of MCF7 and T47D breast cancer culture cells at the Parasitology Laboratory of the Faculty of Medicine, Universitas Gadjah Mada in August 2018. Toxicity tests were carried out using the method of tetrazolium 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT) to calculate cell viability. The IC50 value was obtained by analyzing probit regression calculation using SPSS software. The synergism of this compound with doxorubicin was determined based on the value of the Combination Index (CI) using a combination test with series 1/2 IC50, 3/8 IC50, 1/4 IC50, and 1/8 IC50 and the data was analyzed using Compusyn 1.0 software. In this study, the effect of soursop leaf preparations will be tested on T47D and MCF7 breast cancer cell cultures and assess the impacts of co-chemotherapy of soursop leaf aqueous extract with doxorubicin. This study showed that IC50 soursop leaf aqueous extract in T47D breast cancer culture was 84 μg/mL and in MCF7 166.5 μg/mL. In contrast, the combined test showed that soursop leaf aqueous extract was antagonistic with doxorubicin in both T47D and MCF7 cancer cell cultures.

Keywords: Antagonic effect, breast cancer, doxorubicin, MCF7, soursop leaf, T47D

Efek Antagonis Kombinasi Extrak Air Daun Sirsak dan Dok sorubisin pada Kultur Sel Kanker MCF7 dan T47D

Abstrak
Keberhasilan terapi kanker payudara saat ini masih belum optimal dan terdapat efek samping yang ditimbulkan dari terapi kanker payudara tersebut. Penggunaan kombinasi obat standar dengan herbal sering digunakan sebagai ko-kemoterapi dan diyakini dapat meningkatkan efektivitas obat, tetapi penelitian mengenai efek antagonis kombinasi obat masih sangat terbatas. Penelitian ini mengkaji efek antikanker ekstrak air daun sirsak dan kombinasi dengan doxorubicin pada sel kanker payudara MCF7 dan T47D. Penelitian ini merupakan eksperimental murni secara in vitro pada sel kanker payudara MCF7 dan T47D di Laboratorium Parasitologi Fakultas Kedokteran Universitas Gadjah Mada periode Agustus 2018. Uji toksisitas dilakukan menggunakan metode tetrazolium 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT) untuk menghitung viabilitas sel. Nilai IC50 didapatkan melalui analisis menggunakan perhitungan regresi probit menggunakan perangkat lunak SPSS. Efek sinergis senyawa ini dengan dok sorubisin ditentukan berdasar atas nilai Index Kombinasi (IK) menggunakan uji kombinasi dengan seri 1/2 IC50, 3/8 IC50, 1/4 IC50, dan 1/8 IC50 serta data dianalisis menggunakan perangkat lunak Compusyn 1.0. Efek sediaan daun sirsak pada penelitian ini akan diuji dengan terhadap kultur sel kanker payudara T47D dan MCF7 serta menilai efek ko-kemoterapi ekstrak air daun sirsak dengan dok sorubisin. Hasil penelitian ini menunjukkan bahwa IC50 ekstrak air daun sirsak pada kultur sel kanker T47D adalah 84 μg/mL dan pada kultur sel kanker MCF7 166.5 μg/mL, sedangkan uji kombinasi memperlihatkan bahwa ekstrak air daun sirsak berefek antagonis dengan dok sorubisin pada kultur sel kanker T47D dan MCF7.

Kata kunci: Daun sirsak, dok sorubisin, efek antagonis, kanker payudara, MCF7, T47D

Received: 23 September 2021; 22 December 2021; Accepted: 30 December 2021; Published: 31 December 2021

Correspondence: Dr. Lelly Yuniarti, S.Si., M.Kes. Department Biochemistry, Nutrition and Biomolecular, Faculty of Medicine, Universitas Islam Bandung. Jln. Tamansari No. 22, Bandung 40116, West Java, Indonesia. E-mail: lelly.yuniarti@gmail.com
Introduction

Breast cancer is the most common cancer in women worldwide and second only to lung cancer as a most cancer-related killer in developed countries. Breast cancer is a significant public health problem with estimated new cases worldwide, reaching 1,384,155 and nearly 459,000 deaths. It predicted that the incidence of breast cancer worldwide would earn around 3.2 million new points per year by 2050. Breast cancer is the disease that most often raises new cancer cases in most countries (154 countries). Indonesia is included in 154 countries when viewed from the 2018 global statistical cancer pattern; there are approximately 2.9 million new breast cancer cases with a total mortality rate of 620 thousand.

The success rate of breast cancer therapy has not been 100% certain to eliminate cancer, plus the side effects that arise can cause patients not to conform to treatment. Research is needed for alternative medicine that is more effective than previous treatments and has more minimal side effects. Besides, several studies have shown that Indonesian people have more confidence in herbal medicines because herbal medicines are inherited based on the experience of parents in using these drugs, giving rise to a sense of trust in them.

Indonesia is rich in natural ingredients that can prevent and treat cancer, one of which is soursop (Annona muricata L.), a family of Annonaceae. Soursop contains acetogenin, tannins, flavonoids. Acetogenin has a selective cytotoxic effect on cancer cells and multidrug-resistant cancer cells with minimal toxicity to healthy cells. Flavonoids have a metastatic inhibiting impact on the culture of breast, liver, colon, lung, and ovarian cancer cells. Tannins can inhibit the growth and angiogenesis of Caco-2 colon cancer cells; tannin derivatives have a selective cytotoxic effect on cancer cells by inducing apoptosis.

One cancer treatment strategy to reduce side effects is to use a drug combination. One of the advantages of using various drugs is to increase the efficacy of the therapeutic effect. It also reduces the dose but increases or maintains the same effectiveness to avoid toxic effects. It also minimizes or slows drug resistance occurrence and is selective synergy/synergy efficacy (deadly synergy on cancer cells but not in normal cell host). However, the combination of drugs or the use of drugs simultaneously does not always provide a synergistic effect. Interaction of drug combination can also produce an antagonistic response due to the opposite effect of each drug. A drug interaction is defined as the "pharmacologic response" of a drug administered concomitantly with another substance that can alter the patient’s response to the drug. Consequences of changes in response or reactions from drug-drug interactions (DDI) can be associated with decreasing in drug effect. The purpose of this study was to look at the anticancer and co-chemotherapy activities of soursop leaf aqueous extract against breast cancer cells.

Methods

This study is an in vitro experimental study of MCF7 and T47D breast cancer cultures. The research activity was carried out at the Parasitology Laboratory of the Faculty of Medicine, Universitas Gadjah Mada Yogyakarta, in August 2018. The anticancer test was carried out using the tetrazolium 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT), and cell viability was measured using an ELISA reader with wavelength λ=550–600 nm (595 nm). The test was carried out at soursop leaf aqueous extracts (SLAE) concentration series 250 μg/mL, 125 μg/mL, 62.5 μg/mL, 31.25 μg/mL, 15.625 μg/mL, 7.8125 μg/mL, and 3.906 μg/mL. Whereas doxorubicin was carried out in series of 100 μg/mL, 50 μg/mL, 25 μg/mL, 12.5 μg/mL, 6.25 μg/mL, 3.125 μg/mL, and 1.56 μg/mL. Concentrations that can inhibit 50% of cells (IC50) are determined using probit regression calculations using SPSS software. Then the determination of synergism is measured using a combination test with the concentrations series ½ IC50, ½ IC50, ⅛ IC50, and ⅛ IC50, both SLAE and doxorubicin. Cell viability was determined using an ELISA reader with a wavelength of λ=550–600 nm (595 nm).

Combination Index (CI) values were analyzed using Compusyn 1.0 software with the toxicity criteria based on Baharum et al., namely potent (20 μg/mL), moderate (20–100 μg/mL), weak (>100–1,000 μg/mL), and inactive (>1,000 μg/mL); and synergism using Chou-Talalay criteria, namely additive effect (CI=1), synergistic (C<1), and antagonist (C>1).

This research consists of 2 stages. Phase I is intended to determine the anticancer effect of SLAE compounds on T47D and MCF-7 breast cancer cell cultures. Stage 2 determines the chemotherapy effect of SLAE with doxorubicin.
(DOX) on T47D and MCF-7 breast cancer cell culture.

The Health Research Ethics Committee of the Universitas Islam Bandung Faculty of Medicine has approved this study with a health research approval number: 112/Komite Etik.FK/III/2018.

Results

This study presented the cytotoxic test results of SLAE compound against T47D and MCF-7 breast cancer cell cultures. The MTT method produced IC\textsubscript{50} values of SLAE in T47D cell culture of 86,029 μg/mL, IC\textsubscript{50} MCF-7 166.5 μg/mL, DOX at T47D 10.3 μg/mL, while IC\textsubscript{50} DOX at MCF-7 was 26.8 μg/mL. The average IC\textsubscript{50} values and the standard deviations of SLAE and DOX can be seen in Figure 1.

The results of a combination test of SLAE with DOX on MCF7 are presented in Table 1 and Figure 2. The combination index of SLAE compound and DOX on T47D is shown in Table 2 and Figure 3. Combination Index values indicate that the SLAE compound is antagonistic to DOX on MCF7 and T47D.

Discussion

In developing new anti-cancer drugs as candidates for cancer therapy agents, preclinical testing is crucial to understanding the potential...
for cytotoxic activity. Cytotoxic tests are used as an initial screening to determine the effect of a natural substance in inhibiting tumor cell growth. A compound has anti-cancer properties if it can hinder the development of 50% of tumor cell populations at specific concentrations. The requirement met for the cytotoxicity test system is that the test system must produce a reproducible dose-response curve with low variability. The response criteria must show a linear relationship with the number of cells, and the information obtained from the dose-response curve must be in line with the effect that appears. One method commonly used to determine cell numbers is the MTT.\textsuperscript{16,17}

The MTT method showed IC\textsubscript{50} values of SLAE in T47D cell culture of 86.029 g/mL, and IC\textsubscript{50} MCF-7 166.5 g/mL. This indicates weak cytotoxic activity against breast cancer cells.\textsuperscript{15,18} It is similar to the study by Rady et al.,\textsuperscript{19} which stated that soursop leaves have a cytotoxic effect on the liver (HepG2), breast (MCF-7), cervical (HeLa) cancer cells, and others. This cytotoxic effect occurs because of one of the bioactive components. Soursop is annonaceous acetogenins (AGE). Several purified AGEs showed cytotoxicity against various cancer cells, such as annonacin A or B showed cytotoxicity against HepG2; annomuricin A, B, or C against MCF-7 breast cells; annomuricin A, B, C or E against colonic cells HT-29 and pancreatic cells MIA Paca.\textsuperscript{19,20}

Soursop leaves also trigger cell death through various mechanisms. Research shows increased apoptosis in MB-468 breast cancer cells through caspase three activation. In HT-29 colorectal cancer cells, leaf extract induces apoptosis through the accumulation of reactive oxygen species (ROS) followed by mitochondrial membrane potential (MMP) destruction and caspase activation. It also upregulated Bax and downregulated BCL-2.\textsuperscript{19}

The problems faced in the application of

| SLAE Concentration (μg/mL) | DOX Concentration (μg/mL) | Viability (%) | CI |
|---------------------------|----------------------------|--------------|----|
| 5.15                      | 43.01                      | 0.33         | 2.3|
| 5.15                      | 32.26                      | 0.39         | 7.2|
| 5.15                      | 21.5                       | 0.36         | 12.74|
| 5.15                      | 10.75                      | 0.35         | 15.46|
| 3.86                      | 43.01                      | 0.31         | 26.1|
| 3.86                      | 32.26                      | 0.36         | 9.5 |
| 3.86                      | 21.5                       | 0.38         | 6.5 |
| 3.86                      | 10.75                      | 0.39         | 5.4 |
| 2.57                      | 43.01                      | 0.35         | 7.7 |
| 2.57                      | 32.26                      | 0.33         | 11.5|
| 2.57                      | 21.5                       | 0.32         | 14.13|
| 2.57                      | 10.75                      | 0.33         | 11.51|
| 1.29                      | 43.01                      | 0.32         | 7.11|
| 1.29                      | 32.26                      | 0.36         | 3.24|
| 1.29                      | 21.5                       | 0.3          | 10.7|
| 1.29                      | 10.75                      | 0.32         | 7.09|

Figure 3 Effect Curve of SLAE, DOX, and SLAE-DOX Combination on T47D
chemotherapy are chemotherapeutic agents that are toxic to healthy tissue, decreased immune system, and drug resistance occurs; for this problem, the application of co-chemotherapy or combination therapy is needed. Combination therapy can increase the effectiveness of anticancer agents, use lower anticancer doses, decrease toxicity to healthy tissue, slow down and inhibit drug resistance, and allow synergy efficacy in cancer cells. In determining whether soursop leaf aqueous extract can be a co-chemotherapy with doxorubicin and cisplatin, a potential combination test with isobologram.\textsuperscript{10,12}

We did a combination test of doxorubicin and soursop leaf water extract in this study. The results of the combination index above 1 indicated that the soursop leaf extract and doxorubicin combination was antagonistic. These results are different from previous studies, which showed the synergistic effect of doxorubicin with soursop on 4T1 breast cancer cell culture accompanied by a decrease in ROS yields. It shows the potential of soursop as chemotherapy with antioxidant effects.\textsuperscript{21} The difference may result from different tumor types or can also be caused by both drugs acting on the same receptor, resulting in competitive inhibitors.\textsuperscript{22,23} This study has research limitations because it was only carried out on two cell line cultures and only used one soursop leaf preparation.

Conclusions

The conclusion of this study are soursop leaf aqueous extract has weak anticancer properties against MCF7 and T47D breast cancer cell culture and a combination of soursop leaf aqueous extract compounds and doxorubicin have an antagonistic effect against MCF7 and T47D breast cancer cells.

Conflict of Interest

The authors have no conflict of interest to declare.

Acknowledgment

Researchers would like to thank the Parasitology Laboratory of the Faculty of Medicine, Gadjah Mada University, for providing the opportunity for researchers and the team to conduct research and all those who have helped carry out this research.

References

1. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51.
2. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72(2):333–8.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
4. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.
5. Liana Y. Analisis faktor-faktor yang mempengaruhi keluarga dalam penggunaan obat tradisional sebagai swamedikasi di Desa Tuguharum Kecamatan Madang Raya. JKK. 2017;4(3):121–8.
6. Ismail. Faktor yang mempengaruhi keputusan masyarakat memilih obat tradisional di Gampong Lam Ujong. Idea Nurs J. 2015;6(1):7–14.
7. Rajesh V, Baby Kala M. Antiproliferative and chemopreventive effect of Annona muricata Linn. on Ehrlich ascites carcinoma and benzo[a]pyrene induced lung carcinoma. Orient Pharm Exp Med. 2015;15(4):239–56.
8. Zhou Y, Zhang AH, Sun H, Yan GL, Wang XJ. Plant-derived natural products as leads to antitumor drugs. Plant Sci Today. 2014;1(2):46–61.
9. Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011;29(14):1916–23.
10. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–81.
11. Ashton JC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2015;75(11):2400.
12. Chou TC. Drug combination studies and their
synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–6.
13. Ramos-Esquível A, Viquez-Jaikel Á, Fernández C. Potential drug-drug and herb-drug interactions in patients with cancer: a prospective study of medication surveillance. J Oncol Pract. 2017;13(7):e613–22.
14. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6(7):546–58.
15. Baharum Z, Akim A, Taufiq-Yap Y, Hamid R, Kasran R. In vitro antioxidant and antiproliferative activities of methanolic plant part extracts of *Theobroma cacao*. Molecules. 2014;19(11):18317–31.
16. Kiss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, et al. Cell viability assays. In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, editors. Assay guidance manual [e-book]. Bethesda: Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004 [updated 2016 July 1; cited 2020 July 10]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK144065.
17. van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol. 2011;731:237-45.
18. Caamal-Fuentes EE, Peraza-Sánchez SR, Torres-Tapia LW, Moo-Puc RE. Isolation and identification of cytotoxic compounds from *Aeschynomene fascicularis*, a Mayan medicinal plant. Molecules. 2015;20(8):13563–74.
19. Rady I, Bloch MB, Chamcheu RCN, Banang Mbeumi S, Anwar MR, Mohamed H, et al. Anticancer properties of graviola (*Annona muricata*): a comprehensive mechanistic review. Oxid Med Cell Longev. 2018;2018:1826170.
20. Liu N, Yang HL, Wang P, Lu YC, Yang YJ, Wang L, et al. Functional proteomic analysis reveals that the ethanol extract of *Annona muricata* L induces liver cancer cell apoptosis through endoplasmic reticulum stress pathway. J Ethnopharmacol. 2016;189:210–7.
21. Salsabila IA, Nugraheni N, Ahlina FN, Haryanti S, Meyanto E. Synergistic cotreatment potential of soursop (*Annona muricata* L) leaves extract with doxorubicin on 4T1 cells with antisenescence and anti-reactive-oxygen-species. Iran J Pharm Res. 2021;20(2):57–67.
22. van Leeuwen RWF, Jansman FGA, van den Bemt PMLA, de Man F, Piran F, Vincenten I, et al. Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015;26(5):992–7.
23. van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, et al. Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108(5):1071–8.